Biomarkers /
ERBB2
Back to Biomarkers List
Overview
ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, also known as HER2 and neu) is a gene that encodes for the receptor tyrosine-protein kinase erbB-2. ERBB2 has been found to be amplified with an increased copy number in several cancers (PMID: 20185938). Amplification of ERBB2 promotes tumorigenesis and pathogenesis of several human cancers (PMID: 17471238). Recently, in breast cancer patients without ERBB2 gene amplification, activating ERBB2 mutations have also been identified (PMID: 23220880).
ERBB2 is altered in 4.98% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, bladder urothelial carcinoma, and invasive breast carcinoma having the greatest prevalence of alterations [3].
The most common alterations in ERBB2 are ERBB2 Mutation (2.63%), ERBB2 Amplification (3.30%), ERBB2 Exon 20 Mutation (0.55%), ERBB2 Exon 20 Insertion (0.34%), and ERBB2 S310F (0.31%) [3].
Biomarker-Directed Therapies
ERBB2 is a predictive biomarker for use of trastuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan, aromatase inhibitor, capecitabine, endocrine therapy, cisplatin, docetaxel, paclitaxel, carboplatin, fluorouracil, margetuximab, neratinib, pembrolizumab, pertuzumab/trastuzumab/hyaluronidase, trastuzumab/hyaluronidase, and tucatinib in patients.
Breast carcinoma, adenocarcinoma of the gastroesophageal junction, colorectal carcinoma, gastric carcinoma, and malignant salivary gland neoplasm have the most therapies with ERBB2 as a predictive biomarker.
Of the therapies with ERBB2 as a predictive biomarker, 13 are FDA-approved in at least one clinical setting and 13 have NCCN guidelines in at least one clinical setting.
ERBB2 Amplification, ERBB2 L755S, ERBB2 S310F, ERBB2 V777L, and ERBB2 Y772_A775dup are the top alterations on ERBB2 targeted by therapies [4].
Ado-Trastuzumab Emtansine +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated (as a single agent) for the treatment of patients with HER2+ positive breast cancer in either the adjuvant or metastatic setting who previously received trastuzumab and a taxane, separately or in combination. |
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic). |
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN. |
Fam-Trastuzumab Deruxtecan +
Adenocarcinoma Of The Gastroesophageal Junction -
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting |
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as subsequent line therapy. |
Esophageal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended as subsequent line therapy for patients with HER2-positive disease. |
Gastric Adenocarcinoma -
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN. |
Lapatinib +
Breast Carcinoma -
Margetuximab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated in combination with chemotherapy for metastatic HER2-positive breast cancer that received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. |
Neratinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2-positive breast cancer, both in combination with capecitabine for advanced or metastatic disease with two or more prior anti-HER2 based regimens in the metastatic setting, and as a single agent for extended adjuvant treatment following adjuvant trastuzumab-based therapy. |
Pertuzumab +
Pertuzumab/trastuzumab/hyaluronidase +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2+ breast cancer, for adjuvant treatment or for metastatic disease. Per NCCN, pertuzumab/trastuzumab/hyaluronidase injection for subcutaneous use may be substituted for trastuzumab + pertuzumab in any regimen. |
Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2-overexpressing breast cancer: (1) for metastatic disease with paclitaxel as first-line treatment, and as a single agent after one or more chemotherapy regimens. NCCN recommended with various chemotherapy combinations. (2) for adjuvant treatment with chemotherapy and as a single agent following multi-modality anthracycline based therapy. (3) Also NCCN recommended for neoadjuvant treatment. |
Endometrial Adenocarcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended in combination with carboplatin and paclitaxel for stage III/IV or recurrent, HER2-positive uterine serous carcinoma. |
Gastric Carcinoma -
Malignant Esophageal Neoplasm -
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as a single agent or in combination with docetaxel for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic). |
Trastuzumab/hyaluronidase +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2+ breast cancer, for adjuvant treatment or for metastatic disease. Per NCCN, trastuzumab/hyaluronidase injection for subcutaneous use may be substituted for trastuzumab in any regimen. |
Ado-Trastuzumab Emtansine + Endocrine Therapy +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer. |
Aromatase Inhibitor + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved with letrozole as the aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. NCCN recommended for any aromatase inhibitor. |
Aromatase Inhibitor + Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positve/HER2-positive recurrent or metastastic breast cancer. |
Aromatase Inhibitor + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Capecitabine + Cisplatin + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Capecitabine + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for advanced or metastatic breast cancer that overexpresses HER2 and that had prior therapy including an anthracycline, a taxane, and trastuzumab. |
Capecitabine + Trastuzumab + Tucatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for patients with advanced HER2-positive breast cancer that is unresectable or metastatic, who have received one or more prior treatments. |
Carboplatin + Docetaxel + Trastuzumab +
Cisplatin + Fluorouracil + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Docetaxel + Trastuzumab +
Endocrine Therapy + Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer, with or without chemotherapy. |
Endocrine Therapy + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) | |
| Note: Recommend for HR-positive/HER2-positive breast cancer, with fulvestrant, tamoxifen, or aromatase inhibitor metastastic disease, or with tamoxifen or aromatase inhibitor for adjuvant treatment. |
Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommened for recurrent or metastatic HER2-positive breast cancer, without cytotoxic therapy. |
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as subsequent line therapy. |
Paclitaxel + Pertuzumab + Trastuzumab +
Paclitaxel + Trastuzumab +
Pembrolizumab + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced, unresectable, or metastatic HER2+ gastric or GEJ adenocarcinoma. |
Gastric Adenocarcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced, unresectable, or metastatic HER2+ gastric or GEJ adenocarcinoma. |
Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: FDA approved for HER2-positive breast cancer, for metastatic disease with paclitaxel for with no prior anti-HER2 therapy or chemotherapy in that setting, and for adjuvant and neoadjuvant treatment in combination with chemotherapy. Per NCCN, other chemotherapy combinations, or no chemotherapy combination, are options for these settings. |
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as subsequent line therapy. |
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic). |
Clinical Trials
ERBB2 status serves as an inclusion eligibility criteria in 452 clinical trials, of which 328 are open and 124 are closed. Of the trials that contain ERBB2 status as an inclusion criterion, 5 are early phase 1 (3 open), 114 are phase 1 (74 open), 64 are phase 1/phase 2 (42 open), 198 are phase 2 (151 open), 6 are phase 2/phase 3 (3 open), 55 are phase 3 (45 open), and 10 are no phase specified (10 open).
Trials with ERBB2 status in the inclusion eligibility criteria most commonly target breast carcinoma, malignant solid tumor, adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and gastric carcinoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are ERBB2 Amplification and ERBB2 Mutation [4].
Trastuzumab, pertuzumab, paclitaxel, ado-trastuzumab emtansine, and capecitabine are the most frequent therapies in trials with ERBB2 as an inclusion criteria [4].
Significance of ERBB2 in Diseases
Breast Carcinoma +
ERBB2 is altered in 13.78% of breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 284 clinical trials for breast carcinoma, of which 192 are open and 92 are closed. Of the trials that contain ERBB2 status and breast carcinoma as inclusion criteria, 2 are early phase 1 (1 open), 70 are phase 1 (38 open), 42 are phase 1/phase 2 (29 open), 119 are phase 2 (83 open), 2 are phase 2/phase 3 (0 open), 41 are phase 3 (33 open), and 8 are no phase specified (8 open) [4].
Ado-trastuzumab emtansine, trastuzumab, aromatase inhibitor, lapatinib, pertuzumab/trastuzumab/hyaluronidase, pertuzumab, paclitaxel, neratinib, margetuximab, fam-trastuzumab deruxtecan, endocrine therapy, docetaxel, carboplatin, capecitabine, tucatinib, and trastuzumab/hyaluronidase have evidence of efficacy in patients with ERBB2 mutation in breast carcinoma [4].
Adenocarcinoma Of The Gastroesophageal Junction +
ERBB2 is altered in 19.62% of adenocarcinoma of the gastroesophageal junction patients [3].
ERBB2 is an inclusion criterion in 42 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 32 are open and 10 are closed. Of the trials that contain ERBB2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 8 are phase 1 (6 open), 6 are phase 1/phase 2 (4 open), 19 are phase 2 (16 open), 4 are phase 2/phase 3 (3 open), and 5 are phase 3 (3 open) [4].
Capecitabine, cisplatin, trastuzumab, fluorouracil, fam-trastuzumab deruxtecan, and pembrolizumab have evidence of efficacy in patients with ERBB2 mutation in adenocarcinoma of the gastroesophageal junction [4].
Gastric Adenocarcinoma +
ERBB2 is altered in 10.08% of gastric adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 35 clinical trials for gastric adenocarcinoma, of which 30 are open and 5 are closed. Of the trials that contain ERBB2 status and gastric adenocarcinoma as inclusion criteria, 7 are phase 1 (7 open), 4 are phase 1/phase 2 (3 open), 17 are phase 2 (14 open), 3 are phase 2/phase 3 (3 open), and 4 are phase 3 (3 open) [4].
Fam-trastuzumab deruxtecan, pembrolizumab, and trastuzumab have evidence of efficacy in patients with ERBB2 mutation in gastric adenocarcinoma [4].
Non-Small Cell Lung Carcinoma +
ERBB2 is altered in 3.97% of non-small cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 34 clinical trials for non-small cell lung carcinoma, of which 25 are open and 9 are closed. Of the trials that contain ERBB2 status and non-small cell lung carcinoma as inclusion criteria, 8 are phase 1 (4 open), 7 are phase 1/phase 2 (5 open), and 19 are phase 2 (16 open) [4].
Ado-trastuzumab emtansine and fam-trastuzumab deruxtecan have evidence of efficacy in patients with ERBB2 mutation in non-small cell lung carcinoma [4].
Gastric Carcinoma +
ERBB2 is altered in 10.1% of gastric carcinoma patients [3].
ERBB2 is an inclusion criterion in 29 clinical trials for gastric carcinoma, of which 13 are open and 16 are closed. Of the trials that contain ERBB2 status and gastric carcinoma as inclusion criteria, 13 are phase 1 (4 open), 5 are phase 1/phase 2 (4 open), 8 are phase 2 (4 open), 1 is phase 2/phase 3 (0 open), and 2 are phase 3 (1 open) [4].
Capecitabine, cisplatin, trastuzumab, and fluorouracil have evidence of efficacy in patients with ERBB2 mutation in gastric carcinoma [4].
Colorectal Carcinoma +
ERBB2 is altered in 4.69% of colorectal carcinoma patients [3].
ERBB2 is an inclusion criterion in 16 clinical trials for colorectal carcinoma, of which 12 are open and 4 are closed. Of the trials that contain ERBB2 status and colorectal carcinoma as inclusion criteria, 5 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), and 6 are phase 2 (5 open) [4].
Fam-trastuzumab deruxtecan, lapatinib, trastuzumab, and pertuzumab have evidence of efficacy in patients with ERBB2 mutation in colorectal carcinoma [4].
Esophageal Carcinoma +
ERBB2 is altered in 16.67% of esophageal carcinoma patients [3].
ERBB2 is an inclusion criterion in 7 clinical trials for esophageal carcinoma, of which 4 are open and 3 are closed. Of the trials that contain ERBB2 status and esophageal carcinoma as inclusion criteria, 2 are phase 1 (0 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].
Fam-trastuzumab deruxtecan has evidence of efficacy in patients with ERBB2 mutation in esophageal carcinoma [4].
Malignant Salivary Gland Neoplasm +
ERBB2 is altered in 6.96% of malignant salivary gland neoplasm patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for malignant salivary gland neoplasm, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant salivary gland neoplasm as inclusion criteria, 3 are phase 2 (3 open) [4].
Ado-trastuzumab emtansine, pertuzumab, and trastuzumab have evidence of efficacy in patients with ERBB2 mutation in malignant salivary gland neoplasm [4].
Malignant Solid Tumor +
ERBB2 is altered in 5.44% of malignant solid tumor patients [3].
ERBB2 is an inclusion criterion in 90 clinical trials for malignant solid tumor, of which 66 are open and 24 are closed. Of the trials that contain ERBB2 status and malignant solid tumor as inclusion criteria, 51 are phase 1 (37 open), 19 are phase 1/phase 2 (11 open), and 20 are phase 2 (18 open) [4].
Invasive Breast Carcinoma +
ERBB2 is altered in 13.88% of invasive breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 15 clinical trials for invasive breast carcinoma, of which 14 are open and 1 is closed. Of the trials that contain ERBB2 status and invasive breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 5 are phase 2 (5 open), 6 are phase 3 (6 open), and 1 is no phase specified (1 open) [4].
Esophageal Adenocarcinoma +
ERBB2 is altered in 19.0% of esophageal adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 11 clinical trials for esophageal adenocarcinoma, of which 11 are open and 0 are closed. Of the trials that contain ERBB2 status and esophageal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (7 open) [4].
Breast Adenocarcinoma +
ERBB2 is altered in 13.55% of breast adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 10 clinical trials for breast adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain ERBB2 status and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [4].
Endometrial Carcinoma +
ERBB2 is altered in 8.93% of endometrial carcinoma patients [3].
ERBB2 is an inclusion criterion in 10 clinical trials for endometrial carcinoma, of which 9 are open and 1 is closed. Of the trials that contain ERBB2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [4].
Urothelial Carcinoma +
ERBB2 is altered in 14.87% of urothelial carcinoma patients [3].
ERBB2 is an inclusion criterion in 9 clinical trials for urothelial carcinoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (4 open) [4].
Ovarian Carcinoma +
ERBB2 is altered in 3.28% of ovarian carcinoma patients [3].
ERBB2 is an inclusion criterion in 7 clinical trials for ovarian carcinoma, of which 5 are open and 2 are closed. Of the trials that contain ERBB2 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Head And Neck Squamous Cell Carcinoma +
ERBB2 is altered in 2.81% of head and neck squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 4 are open and 3 are closed. Of the trials that contain ERBB2 status and head and neck squamous cell carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [4].
Pancreatic Carcinoma +
ERBB2 is altered in 2.14% of pancreatic carcinoma patients [3].
ERBB2 is an inclusion criterion in 7 clinical trials for pancreatic carcinoma, of which 6 are open and 1 is closed. Of the trials that contain ERBB2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (5 open) [4].
Inflammatory Breast Carcinoma +
ERBB2 is altered in 21.43% of inflammatory breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for inflammatory breast carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERBB2 status and inflammatory breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].
Biliary Tract Carcinoma +
ERBB2 is altered in 5.41% of biliary tract carcinoma patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for biliary tract carcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (5 open) [4].
Ductal Carcinoma In Situ +
ERBB2 is altered in 3.08% of ductal carcinoma in situ patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for ductal carcinoma in situ, of which 3 are open and 2 are closed. Of the trials that contain ERBB2 status and ductal carcinoma in situ as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 3 are phase 1/phase 2 (1 open) [4].
Bladder Carcinoma +
ERBB2 is altered in 14.96% of bladder carcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for bladder carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [4].
Gallbladder Carcinoma +
ERBB2 is altered in 10.45% of gallbladder carcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for gallbladder carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and gallbladder carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (4 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
ERBB2 is altered in 4.28% of non-squamous non-small cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for non-squamous non-small cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].
Cervical Carcinoma +
ERBB2 is altered in 9.09% of cervical carcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [4].
Lung Adenocarcinoma +
ERBB2 is altered in 4.32% of lung adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for lung adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 status and lung adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [4].
Colorectal Adenocarcinoma +
ERBB2 is altered in 4.69% of colorectal adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for colorectal adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and colorectal adenocarcinoma as inclusion criteria, 4 are phase 2 (3 open) [4].
Prostate Carcinoma +
ERBB2 is altered in 1.14% of prostate carcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for prostate carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and prostate carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Esophageal Squamous Cell Carcinoma +
ERBB2 is altered in 4.73% of esophageal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for esophageal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and esophageal squamous cell carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Cancer +
ERBB2 is altered in 5.14% of cancer patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 1 is phase 1/phase 2 (1 open) [4].
Squamous Cell Lung Carcinoma +
ERBB2 is altered in 2.04% of squamous cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Hepatocellular Carcinoma +
ERBB2 is altered in 0.23% of hepatocellular carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for hepatocellular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Extrahepatic Cholangiocarcinoma +
ERBB2 is altered in 8.97% of extrahepatic cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for extrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and extrahepatic cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Malignant Endometrial Neoplasm +
ERBB2 is altered in 8.72% of malignant endometrial neoplasm patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for malignant endometrial neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant endometrial neoplasm as inclusion criteria, 2 are phase 1 (2 open) [4].
Malignant Uterine Neoplasm +
ERBB2 is altered in 8.03% of malignant uterine neoplasm patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for malignant uterine neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant uterine neoplasm as inclusion criteria, 2 are phase 2 (2 open) [4].
Laryngeal Squamous Cell Carcinoma +
ERBB2 is altered in 2.35% of laryngeal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for laryngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and laryngeal squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Oropharyngeal Squamous Cell Carcinoma +
ERBB2 is altered in 3.6% of oropharyngeal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for oropharyngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Cholangiocarcinoma +
ERBB2 is altered in 4.07% of cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Small Cell Lung Carcinoma +
ERBB2 is altered in 2.64% of small cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Head And Neck Carcinoma +
ERBB2 is altered in 4.04% of head and neck carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Intrahepatic Cholangiocarcinoma +
ERBB2 is altered in 2.89% of intrahepatic cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and intrahepatic cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Oral Cavity Squamous Cell Carcinoma +
ERBB2 is altered in 2.42% of oral cavity squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for oral cavity squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and oral cavity squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Malignant Ovarian Neoplasm +
ERBB2 is altered in 3.38% of malignant ovarian neoplasm patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for malignant ovarian neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant ovarian neoplasm as inclusion criteria, 2 are phase 1 (2 open) [4].
Malignant Glioma +
ERBB2 is altered in 1.71% of malignant glioma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for malignant glioma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Pancreatic Adenocarcinoma +
ERBB2 is altered in 2.15% of pancreatic adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Ependymoma +
ERBB2 is an inclusion criterion in 2 clinical trials for ependymoma, of which 0 are open and 2 are closed. Of the trials that contain ERBB2 status and ependymoma as inclusion criteria, 2 are phase 1/phase 2 (0 open) [4].
Hypopharyngeal Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 2 clinical trials for hypopharyngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Salivary Duct Carcinoma +
ERBB2 is altered in 29.75% of salivary duct carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Adenocarcinoma +
ERBB2 is altered in 18.57% of salivary gland adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Vaginal Neoplasm +
ERBB2 is altered in 14.29% of malignant vaginal neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant vaginal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant vaginal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Breast Invasive Ductal Carcinoma +
ERBB2 is altered in 14.14% of breast invasive ductal carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for breast invasive ductal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and breast invasive ductal carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].
Salivary Carcinoma, NOS +
ERBB2 is altered in 11.11% of salivary carcinoma, NOS patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary carcinoma, NOS, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary carcinoma, NOS as inclusion criteria, 1 is phase 2 (1 open) [4].
Small Intestinal Carcinoma +
ERBB2 is altered in 11.18% of small intestinal carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and small intestinal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Endometrial Serous Adenocarcinoma +
ERBB2 is altered in 11.17% of endometrial serous adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Primary Peritoneal Carcinoma +
ERBB2 is altered in 8.7% of primary peritoneal carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Cervical Neoplasm +
ERBB2 is altered in 9.5% of malignant cervical neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant cervical neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant cervical neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Uterine Corpus Carcinosarcoma +
ERBB2 is altered in 7.17% of uterine corpus carcinosarcoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Carcinoma +
ERBB2 is altered in 6.96% of salivary gland carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ampulla Of Vater Carcinoma +
ERBB2 is altered in 7.94% of ampulla of vater carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Urethral Neoplasm +
ERBB2 is altered in 7.78% of malignant urethral neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant urethral neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant urethral neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Digestive System Carcinoma +
ERBB2 is altered in 6.32% of digestive system carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for digestive system carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and digestive system carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Colorectal Neoplasm +
ERBB2 is altered in 4.69% of malignant colorectal neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant colorectal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant colorectal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Biliary Tract Neoplasm +
ERBB2 is altered in 5.4% of biliary tract neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for biliary tract neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and biliary tract neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Digestive System Neoplasm +
ERBB2 is altered in 5.64% of malignant digestive system neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant digestive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant digestive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Laryngeal Neoplasm +
ERBB2 is altered in 2.35% of malignant laryngeal neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Acinic Cell Carcinoma +
ERBB2 is altered in 2.86% of salivary gland acinic cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland acinic cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland acinic cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Oropharyngeal Carcinoma +
ERBB2 is altered in 3.6% of oropharyngeal carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Hepatobiliary Neoplasm +
ERBB2 is altered in 4.02% of malignant hepatobiliary neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Ovarian Epithelial Tumor +
ERBB2 is altered in 3.41% of malignant ovarian epithelial tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Head And Neck Neoplasm +
ERBB2 is altered in 4.09% of malignant head and neck neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant head and neck neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant head and neck neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Primitive Neuroectodermal Tumor +
ERBB2 is altered in 2.37% of primitive neuroectodermal tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Lip And Oral Cavity Carcinoma +
ERBB2 is altered in 2.42% of lip and oral cavity carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nasal Cavity And Paranasal Sinus Carcinoma +
ERBB2 is altered in 1.41% of nasal cavity and paranasal sinus carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
B-Cell Non-Hodgkin Lymphoma +
ERBB2 is altered in 1.62% of B-cell non-hodgkin lymphoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Central Nervous System Neoplasm +
ERBB2 is altered in 1.38% of malignant central nervous system neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Central Nervous System Neoplasm +
ERBB2 is altered in 1.37% of central nervous system neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Prostate Adenocarcinoma +
ERBB2 is altered in 1.09% of prostate adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gastrointestinal Stromal Tumor +
ERBB2 is altered in 0.54% of gastrointestinal stromal tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Bone Marrow Neoplasm +
ERBB2 is altered in 0.55% of malignant bone marrow neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant bone marrow neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant bone marrow neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Bronchogenic Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Diffuse Intrinsic Pontine Glioma +
ERBB2 is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Diffuse Midline Glioma, H3 K27M-Mutant +
ERBB2 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [4].
Fallopian Tube Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gastric Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gliosarcoma +
ERBB2 is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Vulvar Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for malignant vulvar neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant vulvar neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Metastatic Malignant Neoplasm In The Brain +
ERBB2 is an inclusion criterion in 1 clinical trial for metastatic malignant neoplasm in the brain, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and metastatic malignant neoplasm in the brain as inclusion criteria, 1 is phase 2 (0 open) [4].
Nasopharyngeal Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Pancreatic Ductal Adenocarcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Salivary Gland Carcinoma Ex Pleomorphic Adenoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland carcinoma ex pleomorphic adenoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland carcinoma ex pleomorphic adenoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Mucoepidermoid Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland mucoepidermoid carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland mucoepidermoid carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Small Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland small cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ureter Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
